Mutations and expression of the p53 gene in rat bladder carcinomas and cell lines

M. Asamoto, A. M. Mann, T. L. Macatee, Samuel Monroe Cohen

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Abnormalities of the p53 gene are frequently observed in human tumors, including urinary bladder carcinoma, suggesting that p53 plays an important role in human carcinogenesis. However, its role in rat bladder carcinogenesis is unclear. We investigated p53 gene mutations and expression in rat urinary bladder carcinogenesis in vivo and in Vitro. Fifteen urothelial cell lines, including six untransformed (nontumorigenic) ones, six transformed (tumorigenic) in vitro, and three derived from tumors induced in vivo, were examined for p53 expression by immunochemical analysis and for p53 mutations; in addition, 81 rat bladders were analyzed immunohistochemically for p53 expression, and 23 rat bladder tumors were analyzed for p53 mutations. Four cell lines had mutations in the p53 gene. Two of these were missense point mutations, and the other two were splicing mutations. On the other hand, no mutations were found in the bladder tumors induced in rats. By immunoprecipitation with PAb240, which is supposed to be specific for mutant p53, we detected mutations in three of the cell lines; PAb240 did not react with wild‐type p53. However, in all cell lines and in growing populations of primary cultured bladder urothelial cells, p53 expression was detected immunohistochemically or by western blotting using PAb240 or PAb 421 monoclonal antibodies. In a high percentage of transitional cell carcinomas, wild‐type p53 expression was detected by immunohistochemical analysis with PAb240. These results suggest that p53 gene mutations may not occur frequently in rat bladder carcinogenesis in vivo but may occur in vitro and that p53 overexpression detected immunohistochemically is common and may be related to cell proliferation rather than to the presence of mutations in rat bladder carcinogenesis. © 1994 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)236-244
Number of pages9
JournalMolecular Carcinogenesis
Volume9
Issue number4
DOIs
StatePublished - Jan 1 1994

Fingerprint

p53 Genes
Urinary Bladder
Carcinoma
Cell Line
Mutation
Carcinogenesis
Urinary Bladder Neoplasms
Transitional Cell Carcinoma
Missense Mutation
Immunoprecipitation
Point Mutation
Neoplasms
Western Blotting
Monoclonal Antibodies
Cell Proliferation
Gene Expression

Keywords

  • Immunohistochemistry
  • cell proliferation
  • immunoprecipitation
  • sequencing

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Mutations and expression of the p53 gene in rat bladder carcinomas and cell lines. / Asamoto, M.; Mann, A. M.; Macatee, T. L.; Cohen, Samuel Monroe.

In: Molecular Carcinogenesis, Vol. 9, No. 4, 01.01.1994, p. 236-244.

Research output: Contribution to journalArticle

Asamoto, M. ; Mann, A. M. ; Macatee, T. L. ; Cohen, Samuel Monroe. / Mutations and expression of the p53 gene in rat bladder carcinomas and cell lines. In: Molecular Carcinogenesis. 1994 ; Vol. 9, No. 4. pp. 236-244.
@article{54b29d646bfd4bfc848f34e22495d406,
title = "Mutations and expression of the p53 gene in rat bladder carcinomas and cell lines",
abstract = "Abnormalities of the p53 gene are frequently observed in human tumors, including urinary bladder carcinoma, suggesting that p53 plays an important role in human carcinogenesis. However, its role in rat bladder carcinogenesis is unclear. We investigated p53 gene mutations and expression in rat urinary bladder carcinogenesis in vivo and in Vitro. Fifteen urothelial cell lines, including six untransformed (nontumorigenic) ones, six transformed (tumorigenic) in vitro, and three derived from tumors induced in vivo, were examined for p53 expression by immunochemical analysis and for p53 mutations; in addition, 81 rat bladders were analyzed immunohistochemically for p53 expression, and 23 rat bladder tumors were analyzed for p53 mutations. Four cell lines had mutations in the p53 gene. Two of these were missense point mutations, and the other two were splicing mutations. On the other hand, no mutations were found in the bladder tumors induced in rats. By immunoprecipitation with PAb240, which is supposed to be specific for mutant p53, we detected mutations in three of the cell lines; PAb240 did not react with wild‐type p53. However, in all cell lines and in growing populations of primary cultured bladder urothelial cells, p53 expression was detected immunohistochemically or by western blotting using PAb240 or PAb 421 monoclonal antibodies. In a high percentage of transitional cell carcinomas, wild‐type p53 expression was detected by immunohistochemical analysis with PAb240. These results suggest that p53 gene mutations may not occur frequently in rat bladder carcinogenesis in vivo but may occur in vitro and that p53 overexpression detected immunohistochemically is common and may be related to cell proliferation rather than to the presence of mutations in rat bladder carcinogenesis. {\circledC} 1994 Wiley‐Liss, Inc.",
keywords = "Immunohistochemistry, cell proliferation, immunoprecipitation, sequencing",
author = "M. Asamoto and Mann, {A. M.} and Macatee, {T. L.} and Cohen, {Samuel Monroe}",
year = "1994",
month = "1",
day = "1",
doi = "10.1002/mc.2940090408",
language = "English (US)",
volume = "9",
pages = "236--244",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Mutations and expression of the p53 gene in rat bladder carcinomas and cell lines

AU - Asamoto, M.

AU - Mann, A. M.

AU - Macatee, T. L.

AU - Cohen, Samuel Monroe

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Abnormalities of the p53 gene are frequently observed in human tumors, including urinary bladder carcinoma, suggesting that p53 plays an important role in human carcinogenesis. However, its role in rat bladder carcinogenesis is unclear. We investigated p53 gene mutations and expression in rat urinary bladder carcinogenesis in vivo and in Vitro. Fifteen urothelial cell lines, including six untransformed (nontumorigenic) ones, six transformed (tumorigenic) in vitro, and three derived from tumors induced in vivo, were examined for p53 expression by immunochemical analysis and for p53 mutations; in addition, 81 rat bladders were analyzed immunohistochemically for p53 expression, and 23 rat bladder tumors were analyzed for p53 mutations. Four cell lines had mutations in the p53 gene. Two of these were missense point mutations, and the other two were splicing mutations. On the other hand, no mutations were found in the bladder tumors induced in rats. By immunoprecipitation with PAb240, which is supposed to be specific for mutant p53, we detected mutations in three of the cell lines; PAb240 did not react with wild‐type p53. However, in all cell lines and in growing populations of primary cultured bladder urothelial cells, p53 expression was detected immunohistochemically or by western blotting using PAb240 or PAb 421 monoclonal antibodies. In a high percentage of transitional cell carcinomas, wild‐type p53 expression was detected by immunohistochemical analysis with PAb240. These results suggest that p53 gene mutations may not occur frequently in rat bladder carcinogenesis in vivo but may occur in vitro and that p53 overexpression detected immunohistochemically is common and may be related to cell proliferation rather than to the presence of mutations in rat bladder carcinogenesis. © 1994 Wiley‐Liss, Inc.

AB - Abnormalities of the p53 gene are frequently observed in human tumors, including urinary bladder carcinoma, suggesting that p53 plays an important role in human carcinogenesis. However, its role in rat bladder carcinogenesis is unclear. We investigated p53 gene mutations and expression in rat urinary bladder carcinogenesis in vivo and in Vitro. Fifteen urothelial cell lines, including six untransformed (nontumorigenic) ones, six transformed (tumorigenic) in vitro, and three derived from tumors induced in vivo, were examined for p53 expression by immunochemical analysis and for p53 mutations; in addition, 81 rat bladders were analyzed immunohistochemically for p53 expression, and 23 rat bladder tumors were analyzed for p53 mutations. Four cell lines had mutations in the p53 gene. Two of these were missense point mutations, and the other two were splicing mutations. On the other hand, no mutations were found in the bladder tumors induced in rats. By immunoprecipitation with PAb240, which is supposed to be specific for mutant p53, we detected mutations in three of the cell lines; PAb240 did not react with wild‐type p53. However, in all cell lines and in growing populations of primary cultured bladder urothelial cells, p53 expression was detected immunohistochemically or by western blotting using PAb240 or PAb 421 monoclonal antibodies. In a high percentage of transitional cell carcinomas, wild‐type p53 expression was detected by immunohistochemical analysis with PAb240. These results suggest that p53 gene mutations may not occur frequently in rat bladder carcinogenesis in vivo but may occur in vitro and that p53 overexpression detected immunohistochemically is common and may be related to cell proliferation rather than to the presence of mutations in rat bladder carcinogenesis. © 1994 Wiley‐Liss, Inc.

KW - Immunohistochemistry

KW - cell proliferation

KW - immunoprecipitation

KW - sequencing

UR - http://www.scopus.com/inward/record.url?scp=0028229441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028229441&partnerID=8YFLogxK

U2 - 10.1002/mc.2940090408

DO - 10.1002/mc.2940090408

M3 - Article

VL - 9

SP - 236

EP - 244

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 4

ER -